Insider Selling: RxSight, Inc. (NASDAQ:RXST) CFO Sells 10,000 Shares of Stock

RxSight, Inc. (NASDAQ:RXST) CFO Shelley B. Thunen sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $52.69, for a total transaction of $526,900.00. Following the completion of the transaction, the chief financial officer now owns 13,938 shares in the company, valued at $734,393.22. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

RxSight Trading Up 5.2 %

RXST traded up $2.93 during trading hours on Thursday, hitting $59.63. 473,929 shares of the company’s stock were exchanged, compared to its average volume of 430,080. RxSight, Inc. has a 12-month low of $18.09 and a 12-month high of $59.70. The firm has a 50 day moving average of $52.51 and a 200 day moving average of $42.44. The firm has a market cap of $2.22 billion, a P/E ratio of -41.39 and a beta of 1.21.

RxSight (NASDAQ:RXST) last announced its earnings results on Wednesday, February 28th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.10. RxSight had a negative net margin of 54.57% and a negative return on equity of 31.16%. The firm had revenue of $28.58 million for the quarter, compared to the consensus estimate of $28.60 million. As a group, research analysts expect that RxSight, Inc. will post -0.94 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on RXST shares. Stifel Nicolaus upped their price objective on shares of RxSight from $54.00 to $64.00 and gave the stock a “buy” rating in a report on Thursday, February 29th. Oppenheimer upped their price objective on shares of RxSight from $54.00 to $61.00 and gave the stock an “outperform” rating in a report on Thursday, February 29th. Needham & Company LLC restated a “buy” rating and issued a $64.00 price objective on shares of RxSight in a report on Thursday, April 11th. Finally, JPMorgan Chase & Co. upped their price objective on shares of RxSight from $40.00 to $62.00 and gave the stock an “overweight” rating in a report on Thursday, February 29th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $49.63.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. RiverPark Advisors LLC boosted its holdings in shares of RxSight by 70.0% in the 4th quarter. RiverPark Advisors LLC now owns 668 shares of the company’s stock valued at $27,000 after buying an additional 275 shares in the last quarter. BluePath Capital Management LLC acquired a new stake in RxSight during the 3rd quarter worth $32,000. Amalgamated Bank boosted its stake in RxSight by 7.7% during the 4th quarter. Amalgamated Bank now owns 4,148 shares of the company’s stock worth $167,000 after purchasing an additional 298 shares during the period. Clear Rock Advisors LLC acquired a new stake in RxSight during the 4th quarter worth $172,000. Finally, Clarus Group Inc. acquired a new stake in RxSight during the 4th quarter worth $202,000. Institutional investors and hedge funds own 78.78% of the company’s stock.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.